Kornimate/medical-research-clean huggingface dataset:
efficacy of skin cooling in reducing pain associated with non-invasive treatments of neurofibromatosis type 1 cutaneous neurofibromas

Conditions: Neurofibromatosis 1

Summary: this study will evaluate the effectiveness of skin cooling in increasing tolerability of four treatments in neurofibromatosis type 1 cutaneous neurofibromas. these treatments are: a 980nm laser, a 755nm laser, radio-frequency injection, and a kybella injection. each patient will have a treatment and a control site..


Eligibility criteria:
inclusion criteria: 1. adult ≥18 years of age 2. have a diagnosis of nf1 based on germline genetic testing or by meeting ≥ 2 the following criteria: 1. family history of nf1 2. six or more light brown ("cafe-au-lait") spots on the skin 3. presence of two or more neurofibromas of any type, or one or more plexiform neurofibromas 4. freckling under the arms or in the groin area 5. two or more pigmented, benign bumps on the eye's iris (lisch nodules) 6. a distinctive bony lesion: dysplasia (abnormal growth) of the sphenoid bone behind the eye, or dysplasia of long bones, often in the lower leg 7. tumor on the optic nerve that may interfere with vision 3. patients must be seeking treatment for cnf 4. patients must have ≥ 6 paired cnf (3 to be treated and 3 untreated) that are visible and measure between 2-8mm in size. these must be in areas amenable to treatment and surveillance with digital photography. 5. cnf must be located on the trunk, arms or legs of the patient 6. able and willing to comply with all visit, treatment and evaluation schedules and requirements 7. able to understand and provide written informed consent exclusion criteria: 1. individuals who cannot give informed consent or adhere to study schedule. 2. actively tanning during the course of the study. 3. adverse reactions to compounds of any external agent (e.g., gels, lotions or anesthetic creams) required for use in the study, if no alternative to the said agent exists; 4. known allergy to injectable anesthetics, deoxycholic acid or polidocanol. 5. women who are pregnant. 6. those with acute thromboembolic diseases. 7. those with bleeding abnormalities or those who are currently being treated with antiplatelet or anticoagulant therapy. 8. those with dysphagia. 9. any condition which, in the investigator's opinion, would make it unsafe (for the participant or study personnel) to treat the participant as part of this research study.
a study of zimberelimab(gls-010) combined with avd for newly diagnosed early-stage hodgkin's lymphoma

Conditions: Classical Hodgkin Lymphoma

Summary: this is a multicenter, open-label single-arm phase ii study to evaluate the efficacy and safety of zimberelimab (gls-010) combined with avd for newly diagnosed early-stage hodgkin's lymphoma under the guidance of pet/ct.

despite achieving good disease control and long-term survival rates for over 80% of classical hodgkin lymphoma (chl) patients who receive first-line therapy, approximately 10% of early-stage and 30% of advanced chl patients experience disease relapse or refractoriness after initial treatment, and only half of the patients can be cured through high-dose therapy (hdt) and autologous stem cell transplantation (asct). meanwhile, the current standard first-line treatment still centers around conventional chemotherapy with cytotoxic agents. as such, the clinical challenge of chl first-line treatment lies in striking a balance between efficacy and toxicity, and developing low-toxicity, high-efficiency treatment strategies to achieve the optimal treatment goal of maximizing efficacy while minimizing short- and long-term toxicities.

Eligibility criteria:
inclusion criteria: 1. diagnosed with primary classical hodgkin lymphoma (hl) based on histopathology. 2. stage i-ii . 3. at least one measurable target lesion（lugano 2014）. 4. age 18 years or older (including 18 years) to 45 years (recent fertility requirements and concern about chemotherapy side effects), or age \>60 years (older patients who are frail and unwilling to undergo chemotherapy), male or female. 5. ecog ps 0-3, 6. expected survival ≥ 3 months. exclusion criteria: 1. hodgkin's lymphoma with nodular lymphocyte predominant type. 2. patients who are scheduled to undergo subsequent autologous stem cell transplantation. 3. contraindications to radiotherapy. 4. with central nervous system (meningeal or parenchymal) involvement. 5. contraindications to immune checkpoint inhibitors.

Keywords: zimberelimab pd-1 checkpoint inhibitor avd
measuring consequences of disability for patients with multiple sclerosis and caregivers on economic burden

Conditions: Multiple Sclerosis; Physical Disability; Economic Burden; Social Interaction; Capability; Quality of Life

Summary: the objective of this study is to measure economic burden of multiple sclerosis (ms) from a new point of view that includes consequences of disability on quality of life (qol), social participation and capabilities of patients and caregivers. to the investigators' knowledge, there is currently no data including intangible costs related to caregivers and calculating the overall economic cost of multiple sclerosis, particularly, in france.

the goal of this study is to evaluate prospectively the economic burden of multiple sclerosis (ms) in france by calculating direct costs (medical and non-medical) and indirect costs and by estimating consequences of ms on utility (qaly) of patients and caregivers in a societal perspective.

Eligibility criteria:
inclusion criteria: * participant aged 18 or more * confirmed ms diagnosis (mcdonald 2005) * defined type of ms according classification of lublin and reingold exclusion criteria: * subject living in an institution * severe cognitive dysfunction preventing to answer questionnaire * subject already included in other clinical study (phase 1 to 3)
carbon monoxide monitoring and emergency treatment

Conditions: Carbon Monoxide Poisoning

Summary: carbon monoxide (co) has been called a "silent killer", and those patients who survive co poisoning are at risk of neurological damage, which may be permanent. co is a leading cause of unintentional poisoning deaths in the united states, and the odorless gas results in an estimated average of 20,636 emergency department (ed) visits each year. oxygen is the antidote for co poisoning, and it acts both by attenuating toxic effects and enhancing elimination. a fractional inspired concentration of oxygen (fio2) of 0.7 to 0.9 may be achieved by administration of 100% oxygen delivered using a reservoir with a facemask that prevents rebreathing. hyperbaric oxygen therapy may provide added benefit for patients with co poisoning, but this therapy is unavailable in many parts of the united states including vermont. use of a continuous positive airway pressure (cpap) mask may achieve an fio2 of 1.0, but the effects of delivering an fio2 of 1.0 compared to 0.7 in co poisoning are unknown. cpap, by comparison, is inexpensive, portable, and available in most eds. in this study, the investigators are testing the hypothesis that oxygen delivered by cpap will improve both co washout kinetics and functional outcomes, compared to the standard therapy of oxygen delivered by non-rebreathing facemask. specific aim 1 will provide toxicokinetic data to support a potential benefit in the use of cpap for co poisoning, by comparing co elimination kinetics in response to oxygen therapy delivered by non-rebreathing facemask versus cpap. the 20 patients expected in our first year will provide adequate power to detect a 20% fall in half-time of co elimination. while cpap may increase co washout rates, as predicted in specific aim 1, demonstration of real functional benefit will be tested in specific aim 2. this aim seeks to determine functional (neuropsychological) outcomes in patients with co poisoning treated with oxygen therapy delivered by non-rebreathing facemask versus cpap. data showing a therapeutic benefit from cpap in co poisoning would have clinical implications. compared to hyperbaric oxygen therapy, cpap therapy can begin earlier, including the pre-hospital setting, for patients with known exposure. with the frequent nature of co poisoning and the widespread availability of cpap, a potential benefit could lead to improved outcomes for the 20,000+ patients who present to eds annually.


Eligibility criteria:
inclusion criteria: * elevated carboxyhemoglobin level (non-smokers \>8%, smokers \>12%) * 18 years of age or older * able to provide informed consent as assessed by attending emergency physician exclusion criteria: * requires daily medication for active lung disease * altered mental status * hemodynamically unstable * requires transfer to icu or hyperbaric oxygen facility * previous enrollment in the study * no concurrent acute psychiatric illness

Keywords: carbon monoxide toxicity carbon monoxide poisoning toxicity treatment cpap hyperbaric oxygen
mechanisms of lipodystrophy in hiv-infected pateints

Conditions: HIV Infections

Summary: the metabolic and molecular basis of lipodystrophy syndrome in hiv-infected patients is not known. whether besides protease inhibitors, other antiretroviral drugs, hiv infection and reduction in viral load contribute to the development of lipodystrophy syndrome is not clear. the project therefore has the following aims: 1) to characterize metabolic abnormalities and changes in body fat distribution, 2) to develop objective criteria for defining the syndrome and to ascertain prognostic indicators and 3) to elucidate the molecular basis of the lipodystrophy syndrome in hiv-infected patients.

a 2-year long prospective, randomized, double blind, placebo-controlled study in 200 asymptomatic hiv (+) patients to compare two equally effective antiretroviral regimens, one with and the other without a protease inhibiotor. we will study body fat distribution by anthropometry and magnetic resonance imaging and will measure insulin sensitivity (in a subset of patients), plasma lipoproteins, glucose tolerance and other metabolic variables. we will study expression of an array of adipocyte specific proteins/transcription factors involved in adipocyte differentiation, insulin action and lipoprotein metabolism in fat biopsy samples obtained before and after institution of therapy.

Eligibility criteria:
inclusion criteria: * hiv positive * no previous antiviral therapy * 18 to 70 years of age exclusion criteria: * patients with opportunistic infections or aids. * active intravenous drug users. * patients on corticosteroids, androgens, lipid-lowering drugs, anti-fungal medications, dehydroepiandrosterone, oxandrolone, megace. * patients with diabetes mellitus. * patients with moderate to heavy alcohol consumption ( greater than 15 drinks per week). * pregnant or premenopausal women, unless surgically sterilized or highly unlikely to conceive (defined as women taking oral contraceptives, using barrier protection during intercourse or with a copper intrauterine device in place for \> 3 months without complaints and a negative serum or urine pregnancy test within 30 days of study entry). * acute or chronic liver diseases; elevations of liver transaminases by more than two and one half times above the upper limits of normal ( sgot \> 105 u/l, sgpt \> 120 u/l, ) or a total bilirubin of \> 1.5mg/dl. * anemia (hematocrit \<32%). * abnormal thyroid function tests. * weight loss \>10% from baseline in the past year. * recent (within the past year), history of suicide attempt.

Keywords: hiv lipodystrophy treatment experienced
pecs ii block and pab could be an alternative in breast surgery

Conditions: Breast Cancer

Summary: the association between ultrasound-guided pecs ii block and parasternal block can represent a valid alternative in the management of acute and postoperative pain syndrome after quadrantectomy with or without axillary dissection.

the combination of pecs ii block and pab provides good management of postoperative pain and can be considered a viable alternative to common anesthetic procedures performed for breast cancer surgery.

Eligibility criteria:
inclusion criteria: * 18-75 years of age; * american society of anesthesiologists (asa) physical status i-iii, * patients scheduled for quadrantectomy with or without axillary dissection exclusion criteria: * pregnancy; * body mass index (bmi) \>35; * allergy to local anesthetics; * skeletal or muscle abnormalities of the chest wall; * presence of primary or secondary neurological diseases; * presence of psychiatric diseases; * history of chronic pain or neuropathic disorders; * history of drug abuse; * state of sepsis; * infection * tumors of the skin on the chest; * primary; * secondary coagulopathies
university of oklahoma parenting program attrition

Conditions: Child Abuse

Summary: the study will examine the extent to which a group motivational intervention (me) impacts retention, treatment compliance, and long-term outcomes in families with a history of, or high risk for, child maltreatment.

the field of child abuse prevention faces not only the challenge of developing and disseminating effective treatments, but the problem of high attrition rates and treatment noncompliance. this study will compare the effects of a motivational intervention with a "services as usual" orientation group on program retention, treatment compliance, and long-term outcomes in families with histories of child maltreatment.

Eligibility criteria:
inclusion criteria: * families referred to service agency for child maltreatment prevention services * families with children between 2-1/2 and 12 years of age exclusion criteria: * parents with cognitive, psychiatric, or social conditions that would limit their ability to provide voluntary consent or benefit from the intervention * parents who have sexually abused their children

Keywords: parent training child maltreatment motivation program attrition
study comparing tvt with tvt-secur for the treatment of stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: the purpoe of this study is to compare the safety and efficacy of the tension-free vaginal tape procedure (tvt) to the tvt-secur procedure in the treatment of stress urinary incontinence.


Eligibility criteria:
inclusion criteria: * urinary incontinence symptoms * urodynamic stress incontinence confirmed with multichannel urodynamic testing * age of at least 21 years * desires surgical correction of stress urinary incontinence exclusion criteria: * post-void residual volume \>100cc * detrusor overactivity on preoperative multichannel urodynamic testing * history of previous synthetic, biologic or fascial sub-urethral sling * desires future childbearing * history of bleeding diathesis or current anti-coagulation therapy * current genitourinary fistula or urethral diverticulum * reversible cause of incontinence (i.e. drug effect) * contraindication to surgery

Keywords: stress urinary incontinence sling procedures tension-free vaginal tape
anti-bacterial clinical study on teeth, tongue, cheek, gum, and saliva

Conditions: Plaque, Dental

Summary: this 4-week clinical study was designed to examine the antibacterial efficacy of brushing with a 0.454% stannous fluoride toothpaste with potassium nitrate and pyrophosphate compared to a toothpaste containing 0.76% mfp (marketed as colgate cavity protection toothpaste) in different regions of the mouth (dental plaque, tongue, cheek, gum surface and in saliva) 12 hours post-brushing (overnight) after 2 and 4 weeks of product use.


Eligibility criteria:
inclusion criteria: * male and female subjects, ages 18-70, inclusive. * subject is available during study duration and has no allergies to oral hygiene formulations. * a minimum of 20 natural teeth with facial and lingual scorable surfaces. * a willingness to read, understand, and sign the informed consent form after the nature of the study has been fully explained to them. subject should demonstrate a willingness to comply with all study procedures and clinical examination schedules. * subjects with a baseline whole mouth scores of dental plaque of 1.5 or more \[turesky modification of quigley-hein\] and gingivitis index of 1.0 or more \[loe-silness\]. exclusion criteria: * participation in any other clinical study or test panel including clinical studies with oral hygiene formulations within the one month prior to entry into the study. * history of dental prophylaxis or treatments in the past month or during study duration. * history of medical treatments including antibiotic, anti-inflammatory or anticoagulant therapy during the month preceding study enrollment. * subjects scheduled for medical procedures for the duration of the study. * difficulty complying with study procedures and examinations such as excessive gagging during oral assessment etc. * history of significant adverse effects following use of oral hygiene products such as toothpastes and mouthrinses. allergy to personal care/consumer products or their ingredients. * history of diabetes or hepatic or renal disease, or medical or inflammatory conditions or transmittable diseases, e.g. heart disease or aids. * history of rheumatic fever, heart murmur, mitral valve prolapse or other conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures. * oral soft tissue pathology. * history of active or severe periodontal disease and loose teeth. * gross dental caries, severe generalized cervical abrasion and/or enamel abrasion, large fractured or temporary restorations (based on visual examinations). * fixed or removable orthodontic appliance or removable partial dentures. * self-reported pregnancy or lactation. * subjects known to be an alcoholic, or a recovering alcoholic. * history or current use of recreational drugs or other habit promoting products. * use of phenolic flavored products, such as mint flavored candies and chewing gum, during the study period. * ability to refrain from oral hygiene for twelve (12) hours prior to scheduled visit.

Keywords: bacteria plaque saliva
prevention of venous thromboembolism in patients with acute primary intracerebral hemorrhage

Conditions: Intracerebral Hemorrhage

Summary: * to evaluate the efficacy of using ipc during the acute phase of ich in the prevention of vte. * to assess the safety and efficacy of additional therapy with enoxaparin. * to compare the efficacy and safety of the european and american guideline recommendations. * to provide an efficient and safe thromboprophylaxis for several weeks until the patient is able to walk.

* although it has been poorly investigated, the risk of vte among patients with acute primary intracerebral hemorrhage is generally believed to be at least as high as among patients with ischemic stroke. * the currently available guidelines state that while low doses of subcutaneous heparin or low-molecular-weight heparin may reduce vte, it is possible that their effect is counterbalanced by an increase in hemorrhagic complications. * it is still unclear when (if ever) low-molecular-weight-heparin should be safely initiated in ich patients.

Eligibility criteria:
inclusion criteria: * acute primary ich * \> 17 years * unable to walk * admitted within 12 h after onset of ich * informed consent obtained exclusion criteria: * other type of ich than acute primary intracerebral hemorrhage * patients who need neurosurgery * evidence of vte at screening * thrombolytic treatment within the preceding week * major surgery or major trauma within the preceding 3 months * life expectancy less than 3 months due to comorbid disorders * confirmed malignant disease (cancer) * hepatitis and/or liver cirrhosis * renal failure * infectious disease (hiv, endocarditis etc.) * current of previous hematologic disease * recent active and untreated gastric/duodenal ulcer * allergy or known hypersensitivity to enoxaparin or heparins * known hypersensitivity to benzyl alcohol * women of childbearing age if pregnant * participation in another study within the preceding 30 days

Keywords: thromboprophylaxis prevention of venous thromboembolism after ich enoxaparin intermittent pneumatic compression
effect of systematic dexamethasone on the duration of popliteal nerve block for anesthesia after pediatric ankle surgery

Conditions: Ankle Disease; Foot Deformities; Foot Diseases; Cerebral Palsy

Summary: effect of systematic dexamethasone on the duration of popliteal nerve block after pediatric ankle/foot surgery

this study is proposed to explore the effect of systemic dexamethasone on the duration of popliteal nerve block for analgesia after pediatric ankle surgery. after ankle or foot surgery, children need good analgesia. peripheral nerve blocks have provided a safe, effective method to control early postoperative pain when symptoms are most severe. the safety of local anesthesia is particularly important in children due to the much lower toxicity threshold of local anesthetics. the use of an effective adjuvant, such as dexamethasone, could allow for the use of a higher dilution of local anesthetics while maintaining and enhancing their analgesic effect. there is multiple research where intravenous and perineural dexamethasone use has been compared in adults. however, there is a huge lack of research regarding children. in this study, investigators compare different doses of systemic dexamethasone. before the anesthesia, the patients receive dexamethasone intravenously. groups 2 and 3 have dexamethasone doses of 0.1mg/kg, and 0.2mg/kg. the investigator's goal is to find a dexamethasone dose that is as low as possible but at the same time covers the need for good pain relief and fast recovery postoperatively.

Eligibility criteria:
inclusion criteria: * children scheduled for ankle/foot surgery * body weight \> 5kg exclusion criteria: * infection at the site of the regional blockade * coagulation disorders * immunodeficiency * asa= or \>4 * steroid medication in regular use
methylene blue and ozone in early sepsis

Conditions: Sepsis

Summary: effects of methylene blue and ozone o3 therapy effects in early sepsis management , and their implications upon outcome

effects of methylene blue on inducible nitric oxide messenger rna transcription and protein expression are well evident in vasoplegia ,and septic shock . in the same time , ozone o3 therapy is also valuable in immune-modulation in multiple pathologies . our study collaborate both methylene blue and ozone in early sepsis management , and we will evaluate the global medical progress , icu stay , morbidity and mortality

Eligibility criteria:
inclusion criteria: * early sepsis adults patients exclusion criteria: * cardiac problems glucose-6-phosphate-dehydrogenase insufficiency ozone allergy recent myocardial infarction active hyperthyroidism thrombocytopenia pregnancy contraindications